Target intelligence / Profile preview

Nicotinic acetylcholine receptor α9α10 (nAChR α9α10)

Target
nAChR α9α10
Molecular classification
Ion channel, Ligand-gated ion channel, Nicotinic acetylcholine receptor (cys-loop superfamily member), Pentameric receptor complex
01

Overview

The nicotinic acetylcholine receptor α9α10 is a heteromeric ion channel composed of α9 and α10 subunits, primarily expressed in inner ear hair cells where it mediates olivocochlear efferent control of auditory and vestibular sensory processing. This receptor plays a critical role in sound discrimination and protection against acoustic trauma through cholinergic neurotransmission. The α9α10 receptor is also distributed in the central and peripheral nervous system, where it participates in pain regulation and other physiological processes. A distinctive feature of this receptor is its strict dependence on ligand binding for both assembly and surface expression, distinguishing it from most other nicotinic receptors. Mutations in genes encoding auxiliary subunits required for α9α10 function (TMIE and TMEM132e) cause human deafness, highlighting the therapeutic importance of this receptor for hearing restoration.

Other names
Hair cell nicotinic acetylcholine receptorHeteromeric nicotinic acetylcholine receptor containing α9 and α10 subunitsNeuronal acetylcholine receptor subunit alpha-9 (CHRNA9)Nicotinic acetylcholine receptor α10 subunit
02

Mechanism of action

Drugs targeting this receptor would modulate ion channel activity through ligand binding at the orthosteric site between α9 and α10 subunits, affecting calcium and other ion permeability.

03

Biological functions

Auditory processingVestibular processingAcoustic protectionChronic pain regulationSignal transduction
04

Disease associations

Hearing loss/DeafnessChronic pain
05

Safety considerations

Strict ligand-binding requirement for assembly and surface expression presents a unique challenge for drug development.Full channel activity requires auxiliary subunits (TMIE or TMEM132e), limiting functional reconstitution.Limited CNS expression clarity requires careful target validation for CNS-directed therapeutics.
06

Interacting drugs

Acetylcholine

5 more in the full profile.

Beyond the preview

Go deeper on Nicotinic acetylcholine receptor α9α10 (nAChR α9α10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotinic acetylcholine receptor α9α10 (nAChR α9α10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call